The news directly pertains to Edwards Lifesciences and is important for investors as it provides insight into the company's valuation according to Mizuho. The lowering of the price target might indicate a potential downside, but the maintained 'Buy' rating suggests that Mizuho still sees value in the stock. The impact on the stock price is neutral in the short term as the positive 'Buy' rating balances the negative price target revision.